Abstract | BACKGROUND: PATIENTS AND METHODS: The charts of 27 patients with advanced biliary tract adenocarcinoma treated with GEM/CVI 5-FU at the Princess Margaret Hospital were evaluated for response, survival and toxicity. The treatment consisted of a 30-min infusion of gemcitabine at 900 mg/m(2) on days 1, 8 and 15 of a 28-day cycle plus 5-FU given via a peripherally inserted central line at 200 mg/m(2)/day continuously for 21 days, every 28 days. RESULTS: Objective responses were observed in nine patients (33%; 95% confidence interval 17% to 54%). An additional eight patients (30%) achieved stable disease for a median of 4 months (range 2.3-11). Median time to progression and overall survival were 3.7 and 5.3 months, respectively. Direct chemotherapy-related toxicity was mild, with only 11% grade > or =3 myelosuppression. Central venous catheter complications were common (26%). There were no treatment-related deaths. CONCLUSIONS:
|
Authors | J J Knox, D Hedley, A Oza, L L Siu, G R Pond, M J Moore |
Journal | Annals of oncology : official journal of the European Society for Medical Oncology
(Ann Oncol)
Vol. 15
Issue 5
Pg. 770-4
(May 2004)
ISSN: 0923-7534 [Print] England |
PMID | 15111345
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Deoxycytidine
- Fluorouracil
- Gemcitabine
|
Topics |
- Adenocarcinoma
(drug therapy)
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Bile Duct Neoplasms
(drug therapy, pathology)
- Bile Ducts, Intrahepatic
(pathology)
- Cholangiocarcinoma
(drug therapy, pathology)
- Deoxycytidine
(administration & dosage, analogs & derivatives)
- Disease Progression
- Drug Administration Schedule
- Female
- Fluorouracil
(administration & dosage)
- Gallbladder Neoplasms
(drug therapy, pathology)
- Humans
- Infusions, Intravenous
- Male
- Middle Aged
- Prognosis
- Retrospective Studies
- Survival Analysis
- Treatment Outcome
- Gemcitabine
|